Omeros (OMER) Other financing activities (2020 - 2021)
Omeros recorded quarterly Other financing activities of $241000.0 in Q1 2021, down 96.46% quarter-over-quarter from $6.8 million in Q3 2020.
Omeros' Other financing activities history runs 2 years deep, the most recent figure standing at $241000.0 for Q1 2021.
- In Q1 2021, Other financing activities changed N/A year-over-year to $241000.0; the TTM figure through Dec 2021 stood at $241000.0 (changed N/A YoY), while the FY2025 annual figure was $2.8 million, changed N/A from the prior year.
- Other financing activities came in at $241000.0 for Q1 2021 at Omeros, down from $6.8 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $6.8 million in Q3 2020 to a low of $241000.0 in Q1 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 241,000.00 |
| Mar 31, 2021 | 241,000.00 |
| Sep 30, 2020 | 6.80 Mn |
| Sep 30, 2020 | 6.80 Mn |